Drug Discovery World

NOVEMBER 1, 2022

Researchers say they have successfully used a cell’s natural process for making proteins to ‘slide’ genetic instructions into a cell and produce critical proteins missing from those cells. . Current minipromoter systems typically get the proteins in the right place about 5% of the time. . Initial success in the lab.

Gene Expression 52

Gene Expression Gene Packaging Packaging 52

XTalks

OCTOBER 21, 2020

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. The researchers focused on the spike proteins that protrude from the surface of the coronavirus, which are responsible for viral attachment and entry into host cells.

RNA 98

RNA Protein Genome Genomics 98

Drug Discovery World

APRIL 17, 2024

JMB: Regulatory RNAs (or regRNAS) are molecules that directly control the expression of nearby protein-coding genes. So, regRNAs haven’t been exploited previously because scientists have only recently understood their role in regulating gene expression. What is regRNA and why hasn’t it been exploited as a therapeutic target before?

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

XTalks

MARCH 18, 2024

By genetically editing microorganisms, scientists can now manipulate the metabolic pathways to produce foods with desirable properties. The precision fermentation study highlights how genetically engineered microorganisms can inhibit the growth of foodborne pathogens.

Genetic Engineering 52

Genetic Engineering Genetics Production Protein 52

Drug Discovery World

MARCH 2, 2023

Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome. But the new findings answer a fundamental and longstanding question – how epigenetic proteins regulate the processes of transcription and gene expression, through which our genes are read and translated into proteins.

Gene Expression 52

Gene Expression Gene DNA RNA 52

pharmaphorum

SEPTEMBER 9, 2020

Geneticist Dr Charles Steward has spent his career studying the human genome – but his work became much more personal when his children were diagnosed with severe neurological diseases. Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate.

Genome 85

Genome Genomics Genetics Genome Project 85

Scienmag

APRIL 16, 2021

Scientists have figured out how to modify CRISPR’s basic architecture to extend its reach beyond the genome and into what’s known as the epigenome — proteins and small molecules that latch onto DNA and control when and where genes are switched on or off.

DNA 40

DNA Genome Genomics Gene 40

XTalks

JULY 14, 2022

For example, when T cells (a type of white blood cells that fight off infections and cancer) are activated in our immune systems, thousands of proteins in these cells change. The proteins are interconnected and changes in one protein level can impact that of another.

Gene 98

Gene Regulation Protein Gene Editing 98

pharmaphorum

SEPTEMBER 9, 2020

Geneticist Dr Charles Steward has spent his career studying the human genome – but his work became much more personal when his children were diagnosed with severe neurological diseases. Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate.

Genome 71

Genome Genomics Genetics Genome Project 71

pharmaphorum

FEBRUARY 1, 2022

2 is now the dominant strain of the COVID-19 virus in Denmark, and scientists from the country’s Statens Serum Institute (SSI) have compared the two subvariants in more than 8,500 households including almost 18,000 people. The new BA.2 2 subvariant of Omicron is around 50% more transmissible than the original BA.1

Vaccination 98

Vaccination Vaccine Scientist Genome 98

pharmaphorum

JANUARY 24, 2022

Some scientists have given it the nickname ‘stealth variant’, because it is more difficult to detect than BA.1 1 and doesn’t share the genetic deletion on the spike protein that has been used to monitor the spread of Omicron and distinguish it from Delta, which fuelled the last wave of COVID-19 cases. .

Vaccination 98

Vaccination Vaccine Genome Genomics 98

pharmaphorum

JANUARY 20, 2021

A genomic analysis of the SARS-CoV-2 coronavirus, which causes COVID-19, shows that the virus accumulates around two mutations a month. The new variant identified in the UK in December shows significant mutations in the Spike protein and receptor binding domain that increase its infectivity.

Vaccination 52

Vaccination Vaccine Protein RNA 52

Drug Discovery World

MARCH 7, 2023

More research work focuses on dissecting the genetic architecture of other diseases such atrial fibrillation and arrhythmia,” Dr Saad says. More research work focuses on dissecting the genetic architecture of other diseases such atrial fibrillation and arrhythmia,” Dr Saad says.

Biobanking 52

Biobanking Drugs Genome Genomics 52

Drug Discovery World

FEBRUARY 6, 2024

Sanofi has stated that it intends to become the first pharma company “powered by AI at scale”, and as part of this ambition, agreed a collaboration with BioMap to co-develop advanced AI models and protein Large Language Models that that it hopes will enable biologics design and multiparametric optimisation 2.

Marketing 69

Marketing Medicine Genome Genomics 69

Drug Discovery World

MAY 5, 2023

Anthony Schmitt , PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. But what about the patients whose genomic tests do not identify a cancer driver matched to an existing targeted therapy? with regards to detecting cancer driver mutations.

Genome 52

Genome Genomics Gene Genetics 52

Drug Discovery World

DECEMBER 12, 2022

According to the publication, “A small clinical trial has shown that researchers can use CRISPR gene editing to alter immune cells so that they will recognise mutated proteins specific to a person’s tumours. In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments. Analysis .

Drugs 52

Drugs Gene Editing Genome Genomics 52

pharmaphorum

MARCH 10, 2021

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the case of AML that emerged in a trial of the drug in sickle cell disease. bluebird bio’s Philip Gregory.

Gene Therapy 52

Gene Therapy Gene Trials Gene Expression 52

pharmaphorum

SEPTEMBER 14, 2020

Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential.

Genome 114

Genome Genomics Medicine Gene 114

XTalks

FEBRUARY 11, 2021

The Human Genome Project recently marked 20 years since the publication of the first full sets of human genomic sequences, an endeavor that spanned well over a decade. Today, new next-generation sequencing technologies allow for the sequencing of complex genomes within just a day or two. Rosalind Franklin.

Genetics 119

Genetics DNA Genome Genomics 119

Drug Discovery World

OCTOBER 16, 2023

From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). Emerging UK biotech firms like Mosaic Therapeutics, Enhanc3D Genomics, and Nucleome Therapeutics are using these genomic insights to innovate.”

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

APRIL 14, 2023

The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. Dalla-Favera’s award lecture will be held on Tuesday April 18 at 3:45pm ET.

Genetics 52

Genetics Research Medicine Clinical Research 52

The Pharma Data

JULY 8, 2021

Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE). About the UK Biobank.

Genetics 52

Genetics Biobanking Protein Containment 52

The Pharma Data

JULY 15, 2021

The access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE).

Biobanking 52

Biobanking Genetics Protein Medicine 52

Drug Discovery World

MARCH 1, 2023

Avtar Singh is a Senior Scientist in the Cell and Tissue Genomics Department at Genentech, where he develops new approaches for image-based screening and high-throughput biological discovery. DDW’s Megan Thomas spoke with Singh about SLAS2023, where he presented Image-based screening of pooled genetic libraries.

Genetics 52

Genetics Genome Genomics Genotype 52

Drug Discovery World

OCTOBER 4, 2022

As it stands, there are currently 19 gene therapies approved for clinical use, alongside 18 RNA therapies and 59 non-genetically modified cell therapies, according to the Q2 report by the American Society of Cell & Gene Therapy. In the UK, effort has been made to scale-up the country’s cell and gene therapy manufacturing capabilities.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. This is essential to its use as a therapeutic agent and gives the technology a vast versatility making it suitable to treating a wide range of diseases – especially those that have high protein expression.

RNA 52

RNA Protein Vaccination Vaccine 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. They compared these sequences with the original SARS-CoV-2 genome, cross-checking the genetic changes against their highly networked epitopes. 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Roots Analysis

AUGUST 31, 2023

Nutrigenomics is the science studying the relationship between human genome, nutrition and health. In part, the success of the Human Genome Project has also paved a path for the novel concept of nutrigenomics. It further highlights the variation in the genome of patients and identify the sites of metabolic weakness.

Genome 40

Genome Genomics Genetics Gene 40

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

AUGUST 10, 2022

Later, scientists took advantage of antibodies’ natural tendency to seek out specific antigens and created antibody therapies that guide T cells towards the cells they are supposed to destroy. To overcome this evasion tactic, the CAR protein was developed to recognise other markers on cancer cells.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Drug Discovery World

APRIL 14, 2023

DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick , about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. These mutated proteins then reprogramme the epigenome, from which the cancer develops.

Protein 52

Protein Genome Genomics DNA 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 95

Gene Editing Gene DNA Engineer 95

XTalks

JANUARY 14, 2021

False negative results can occur with any molecular test, particularly if a mutation occurs in the part of the virus’s genome assessed by that test. Hahn, MD said, “The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients.”.

Genetics 98

Genetics Genome Genomics Protein 98

Drug Discovery World

FEBRUARY 28, 2023

As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta , PhD, staff scientist in genetic sciences at Thermo Fisher Scientific.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kathrin Herbst, PhD, Director of Science & Business Development, Lightcast, on: ‘A new era of single-cell functional profiling for drug discovery’.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

SEPTEMBER 5, 2022

Genome interpretation: To decipher genetic variants in cancer . The success of targeted therapies in cancer comes on the heels of identifying specific molecular targets resulting from genetic variations. When selecting patients for therapy, we currently look at variants that directly affect protein expression or function.

Development 52

Development Drugs Protein Genome 52

pharmaphorum

APRIL 5, 2022

The technique uses artificial intelligence (AI) to analyse protein data harvested from tumour cells, using an algorithm trained by looking at changes to 52 proteins when they are exposed to a panel of targeted anticancer drugs. The post AI test could predict best cancer therapies for patients appeared first on.

Protein 67

Protein Genetic Analysis Genome Genomics 67